Giuseppe Aprile
Impact in
- Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Pancreatic and Hepatic Oncology Research
- Gastroenterology top 0.2%
- Gastrointestinal Tumor Research and Treatment
Papers in
- Oncology 159
- Colorectal Cancer Treatments and Studies 86
- Pancreatic and Hepatic Oncology Research 26
- Cancer Treatment and Pharmacology 17
- Cancer Immunotherapy and Biomarkers 15
-
- Gastric Cancer Management and Outcomes 44
- Co-authors
- Eric Van Cutsem (3 shared papers)Yoon‐Koo Kang (2 shared papers)Yung‐Jue Bang (2 shared papers)Florian Lordick (2 shared papers)Lin Shen (1 shared paper)Josef Rüschoff (1 shared paper)Michaela Lehle (1 shared paper)Akira Sawaki (1 shared paper)
- Journals
- Annals of Oncology (20 papers)European Journal of Cancer (19 papers)Future Oncology (13 papers)Critical Reviews in Oncology/Hematology (9 papers)British Journal of Cancer (8 papers)
- Partner nations
- ItalyUnited StatesSpain
In The Last Decade
Giuseppe Aprile
293 papers receiving 17.4k citations
Giuseppe Aprile's Hit Papers
Peers
Comparison fields: 5 of 141
- Oncology 8.1k
- Gastroenterology 1.4k
- Pulmonary and Respiratory Medicine 6.3k
- Cancer Research 1.7k
- Pathology and Forensic Medicine 1.6k
Countries citing papers authored by Giuseppe Aprile
This map shows the geographic impact of Giuseppe Aprile's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giuseppe Aprile with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giuseppe Aprile more than expected).
Fields of papers citing papers by Giuseppe Aprile
This network shows the impact of papers produced by Giuseppe Aprile. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giuseppe Aprile. The network helps show where Giuseppe Aprile may publish in the future.
Co-authors
The 25 scholars most cited alongside Giuseppe Aprile, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 304 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Hit paper breakdown → | 2010 | 5913 |
| 2 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial Hit paper breakdown → | 2013 | 1781 |
| 3 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2018 | 1056 |
| 4 | Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 520 |
| 5 | Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan Hit paper breakdown → | 2018 | 349 |
| 6 | 2015 | 260 | |
| 7 | 2020 | 256 | |
| 8 | 2019 | 241 | |
| 9 | 2017 | 227 | |
| 10 | Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial Hit paper breakdown → | 2022 | 211 |
| 11 | 2014 | 204 | |
| 12 | 2019 | 190 | |
| 13 | 2015 | 143 | |
| 14 | 2015 | 136 | |
| 15 | 2020 | 133 | |
| 16 | 2016 | 130 | |
| 17 | 2015 | 123 | |
| 18 | 2017 | 95 | |
| 19 | 2016 | 90 | |
| 20 | 2017 | 89 |
About Giuseppe Aprile
Giuseppe Aprile is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Gastroenterology and Surgery, having authored 304 papers that have together received 17.7k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (86 papers), Gastric Cancer Management and Outcomes (44 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (28 papers), Pancreatic and Hepatic Oncology Research (26 papers), Cancer Genomics and Diagnostics (19 papers), Cancer Treatment and Pharmacology (17 papers), Hepatocellular Carcinoma Treatment and Prognosis (15 papers) and Cancer Immunotherapy and Biomarkers (15 papers). The work is most often cited by research in Oncology (8.1k citations), Gastroenterology (1.4k citations), Pulmonary and Respiratory Medicine (6.3k citations), Cancer Research (1.7k citations) and Pathology and Forensic Medicine (1.6k citations). Giuseppe Aprile has collaborated with scholars based in Italy, United States and Spain. Frequent co-authors include Eric Van Cutsem, Yoon‐Koo Kang, Yung‐Jue Bang, Florian Lordick, Lin Shen, Josef Rüschoff, Michaela Lehle, Akira Sawaki, Andrea Feyereislova and Atsushi Ohtsu. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Future Oncology, Critical Reviews in Oncology/Hematology and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.